Compare PNTG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | TBPH |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2019 | 2013 |
| Metric | PNTG | TBPH |
|---|---|---|
| Price | $33.85 | $18.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $36.50 | $29.20 |
| AVG Volume (30 Days) | 288.6K | ★ 418.7K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | 0.84 | ★ 0.88 |
| Revenue | ★ $947,705,000.00 | $15,386,000.00 |
| Revenue This Year | $36.42 | $70.90 |
| Revenue Next Year | $23.99 | N/A |
| P/E Ratio | $40.07 | ★ $20.64 |
| Revenue Growth | ★ 36.31 | N/A |
| 52 Week Low | $21.18 | $7.90 |
| 52 Week High | $35.00 | $21.03 |
| Indicator | PNTG | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.02 | 46.39 |
| Support Level | $26.65 | $18.27 |
| Resistance Level | N/A | $19.04 |
| Average True Range (ATR) | 1.57 | 0.88 |
| MACD | 0.14 | -0.13 |
| Stochastic Oscillator | 83.59 | 42.38 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).